PDCD6IP

Across TCGA pan-cancer cohorts, PDCD6IP Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PDCD6IP data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PDCD6IP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDCD6IP expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, COAD, and BLCA are the cancer types where PDCD6IP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.246	0.711	<.001	16	view →
COAD	OS	Median	All	0.111	0.871	<.001	14	view →
BLCA	OS	Median	II,III,IV	1.000	0.409	.017	12	view →
LUSC	OS	Median	II,III,IV	0.216	0.631	.027	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	II,III,IV	0.158	0.749	.006	6	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PDCD6IP–LIHC (OS)

Open the LIHC breakdown →